Work Here?
Eikon Therapeutics
Work Here?
Biotech startup developing innovative medicines
Eikon Therapeutics
Work Here?
Biotech startup developing innovative medicines
About Eikon Therapeutics
Industries
AI & Machine Learning
Biotechnology
Company Size
201-500
Company Stage
Series D
Total Funding
$1.1B
Headquarters
Hayward, California
Founded
2019
Overview
Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking (SMT) platform to visualize protein motion in living cells, combined with artificial intelligence and automation for precise analysis of molecular interactions. Their diverse team integrates science and engineering to create therapies aimed at improving the lives of patients with serious diseases. Eikon's goal is to leverage advanced technologies to develop effective treatments for those in need.
Simplify's Take
What believers are saying
- Eikon raised $350.7 million in Series D funding, boosting clinical-stage programs.
- The company is advancing Phase 3 cancer treatments, including melanoma immunotherapy.
- Strong investor confidence is evident with backing from Lux Capital and Soros Capital.
What critics are saying
- Intellectual property disputes may arise over single-molecule tracking technology.
- High valuation could attract regulatory scrutiny and financial compliance issues.
- Significant real estate investments pose financial risks if growth projections falter.
What makes Eikon Therapeutics unique
- Eikon uses proprietary single-molecule tracking for real-time protein movement analysis.
- The company integrates AI and advanced automation in drug discovery processes.
- Eikon's diverse team combines expertise in biology, engineering, and chemistry.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1122.5M
Above
Industry Average
Funded Over
4 Rounds
General CatalystIndustry standards
Benefits
401(k) Company Match
Medical (premiums covered by Eikon at 95%)
Dental Insurance
Vision Insurance
Mental Health Support
Unlimited Paid Time Off
Paid Holidays
Life Insurance
Enhanced Parental Leave
Daily subsidized lunch program
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 6%Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.
Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a
Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.
Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.
Eikon Therapeutics is Hiring for 20 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Eikon Therapeutics
Industries
AI & Machine Learning
Biotechnology
Company Size
201-500
Company Stage
Series D
Total Funding
$1.1B
Headquarters
Hayward, California
Founded
2019
Eikon Therapeutics is Hiring for 20 Jobs on Simplify!
Find jobs on Simplify and start your career today